메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose: To evaluate how much the improvement of lower urinary tract symptoms(LUTS) affects sexual function and which storage symptoms or voiding symptoms havethe greatest effect on sexual function. Materials and Methods: A total of 187 patients were enrolled in this study. Patientswere randomly assigned to receive either tamsulosin 0.2 mg (group A) or tamsulosin0.2 mg and solifenacin 5 mg (group B). At 4 weeks and 12 weeks, the LUTS and sexualfunction of the patients were evaluated by use of the International Index of ErectileFunction-5 (IIEF5), International Prostate Symptom Score (IPSS), Overactive BladderSymptom Score (OABSS) questionnaire, uroflowmetry, and bladder scan. Results: Both groups A and B showed statistically significant improvements in IPSS,OABSS, and quality of life (QoL). Group A showed improved maximum flow rate, meanflow rate, and residual urine volume by time. Group B did not show an improvementin flow rate or residual urine volume but total voiding volume increased with time. TheIIEF5 score was not improved in either group. In group A, the IIEF5 score dropped from13.66±4.97 to 11.93±6.14 after 12 weeks (p=0.072). Group B showed a decline in theIIEF5 score from 13.19±5.91 to 12.45±6.38 (p=0.299). Although group B showed a relativelysmaller decrease in the IIEF5 score, the difference between the two groups wasnot significant (p=0.696). Conclusions: Tamsulosin monotherapy and combination therapy with solifenacin didnot improve erectile function despite improvements in voiding symptoms and QoL. Theimprovement in storage symptoms did not affect erectile function.

목차

등록된 정보가 없습니다.

참고문헌 (23)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0